The effect of melatonin on the quality of sleep in COVID-19 patients
Phase 3
Recruiting
- Conditions
- COVID-19.Coronavirus infection, unspecifiedB34.2
- Registration Number
- IRCT20200411047030N1
- Lead Sponsor
- Mazandaran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 82
Inclusion Criteria
Consent to attend the study
Clinical symptoms
Lymphocyte count less than 1100
Positive CT scan or C-reactive protein
Exclusion Criteria
Epilepsy
Taking warfarin and other anticoagulants and coagulation disorders
Uncontrolled diabetes and high blood pressure
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Stop the fever. Timepoint: It will be reviewed for 7 days from the study onset. Method of measurement: It is recorded by a thermometer.;Transfer to ICU. Timepoint: A maximum of 10 days of hospitalization will be checked. Method of measurement: Tracking hospitalized patients through questions and recording in questionnaires.;Mortality. Timepoint: A maximum of 10 days of hospitalization will be checked. Method of measurement: Tracking hospitalized patients through questions and recording in questionnaires.;Sleep quality. Timepoint: Days 1, 2, 3, and 7. Method of measurement: The Leeds Sleep Evaluation questionnaire will be used.
- Secondary Outcome Measures
Name Time Method ymphopenia status. Timepoint: It will be reviewed on the first day and day 7. Method of measurement: Cell counter device.;C-reactive protein status. Timepoint: It will be reviewed on the first day and day 7. Method of measurement: Serology test.;Peripheral capillary oxygen saturation (SPO2). Timepoint: It will be reviewed on the first day and day 7. Method of measurement: Pulse Oximeter.